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Abstract
Background: A newly defined Cordyceps species, Ophiocordyceps formosana (O. formosana) has been implicated in
multitudinous bioactivities, including lowering glucose and cholesterol levels and modulating the immune system.
However, few literatures demonstrate sufficient evidence to support these proposed functions. Although the use of
Cordyceps spp. has been previously addressed to improve insulin insensitivity and improve the detrimental
symptoms of depression; its mechanistic nature remains unsettled. Herein, we reveal the effects of O.
formosana in ameliorating hyperglycemia accompanied with depression.
Methods: Diabetes was induced in mice by employing streptozotocin(STZ), a chemical that is toxic to insulin-producing
β cells of the pancreas. These streptozotocin (STZ)-induced diabetic mice showed combined symptoms of
hyperglycemia and depressive behaviors. Twenty-four STZ-induced mice were randomly divided into 3 groups
subjected to oral gavage with 100 μL solution of either PBS or 25 mg/mL Ophiocordyceps formosana extract
(OFE) or 2 mg/mL rosiglitazone (Rosi, positive control group). Treatments were administered once per day for
28 days. An additional 6 mice without STZ induction were treated with PBS to serve as the control group.
Insulin sensitivity was measured by a glucose tolerance test and levels of adiponectin in plasma and adipose
tissue were also quantified. Behavioral tests were conducted and levels of monoamines in various brain
regions relating to depression were evaluated.
Results: HPLC analysis uncovered three major constituents, adenosine, D-mannitol and cordycepin, within O.
formosana similar to other prestigious medicinal Cordyceps spp.. STZ-induced diabetic mice demonstrated
decreased body weight and subcutaneous adipose tissue, while these symptoms were recovered in mice
receiving OFE treatment. Moreover, the OFE group displayed improved insulin sensitivity and elevated
adiponectin within the plasma and adipose tissue. The anti-depressive effect of OFE was observed in various
depression-related behavior tests. Concurrently, neurotransmitters, like 5-HT and dopamine in the frontal
cortex, striatum and hippocampus were found to be up-regulated in OFE-treated mice.
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Conclusions: Our findings illustrated, for the first time, the medicinal merits of O. formosana on Type I
diabetes and hyperglycemia-induced depression. OFE were found to promote the expression of adiponectin,
which is an adipokine involved in insulin sensitivity and hold anti-depressive effects. In addition, OFE
administration also displayed altered levels of neurotransmitters in certain brain regions that may have
contributed to its anti-depressive effect. Collectively, this current study provided insights to the potential
therapeutic effects of O. formosana extracts in regards to hyperglycemia and its depressive complications.
Keywords: Ophiocordyceps formosana, Insulin insensitivity, Depression
Abbreviations: 5-HT, 5-hydroxytrptamine; DOPA, Dopamine; EPM, Elevated plus maze; IPGTT, Intraperitoneal
glucose tolerance test; NE, Norepinephrine; OFE, Ophiocordyceps Formosana extract; OFT, Open filed test;
Rosi, Rosiglitazone; SAT, Subcutaneous white adipose tissue; SSRI, Serotonin re-uptake inhibitor; STZ, Streptozoticin;
T1D, Type 1 diabetes; T2D, Type 2 diabetes; TCA, Tricyclic antidepressants; TCM, Traditional Chinese medicine; TST, Tail
suspension test; TZD, Thiazolidinedione
Background
Type I diabetes (T1D) is an autoimmune disease caused
by an immune response against the β cell antigens in the
pancreas, which results in a lack of insulin, but an in-
crease in blood and urine glucose levels [1]. In 2014, an
estimate of 3 million people was reported to have T1D
in the USA [2]. Current therapies for T1D place strong
emphasis on insulin replacement or transplantation of
insulin secreting tissues; however, numerous limitations
and complications still remain. However, Gunawardana
et al. [3] argued that adipose tissues are able to maintain
glucose homeostasis in the absence of insulin; while adi-
pokines have been shown to ameliorate both type 1 and
2 diabetic phenotypes in the absence of exogenous insu-
lin by potentiating insulin receptor sensitivity [3–5]. Past
literatures have shown a positive correlation between
adiponectin levels and insulin sensitivity in T1D patients
[6]; moreover, higher levels of adiponectin is found to be
associated with lower prevalence of metabolic syndrome
in T1DM [7]. In addition, STZ-induced type 1 diabetic
mice displayed ameliorated hyperglycemic symptoms
following adiponectin gene delivery into mice [3]. Con-
sequently, an increase in the level of plasma adiponectin
was found to improve insulin resistance [4].
Depression is commonly linked with hyperglycemia in
T1D and T2D patients [8, 9] and is found to be more
prevalent in T1D patients according to the Beck Depres-
sion Inventory Score [10]. Previous studies suggest that
approximately 15 % of diabetic patients risk complications
of clinical depression [8]. Thus, patients with type I dia-
betes also require the increased use of antidepressants
[11]. Selective serotonin re-uptake inhibitors (SSRIs) are
widely used as the first-line treatment for depression;
however, several side effects, including nausea, anorexia
and sexual dysfunction, are commonly observed [12, 13].
Unfortunately, SSRIs can lead to failure of glycemic con-
trol in diabetic patients. On the other hand, tricyclic anti-
depressants (TCAs) can also contribute to hyperglycemia
in humans and mice [14]. Interestingly, a study showed
that diabetic patients treated with Rosi for 12 weeks ex-
hibited a significant decline in depressive severity as evalu-
ated by the Hamilton Depression Rating Scale and the
Clinical Global Impression Scale [15]. However, the side
effects of Rosi include increase risk of myocardial infarc-
tion [16]. Thus, an effective alternative treatment with lit-
tle or no side effects for T1D and depression-related
complications is still in demand.
Many psychiatric disorders, such as anxiety and de-
pression, can be ascribed to deficits in monoamine neu-
rotransmitters [17, 18]. Thus, many antidepressants are
aimed toward modulating the neurotransmission system
by increasing the content and amount of monoamines
(e.g., dopamine, 5-hydroxytryptamine, and norepineph-
rine) in the limbic regions of the brain. The hypothal-
amic serotonin is increased during insulin-induced
hypoglycemia[19], indicating that glycemic homeostasis
may be beneficial for ameliorating depression. As a re-
sult, adipokines (e.g., leptin and adiponectin) can pro-
mote insulin sensitivity as well as alleviate depressive
behaviors [20, 21].
Some Cordyceps spp. have been used in traditional
Chinese medicine (TCM) to lower blood pressure, glu-
cose and cholesterol, as well as to modulate immune
function [22]. Aside from ameliorating metabolic dys-
functions, Cordyceps spp. also improve psychological dis-
order like insomnia, dysphoria and sleep [23]. Even
though the scientific reports to address Cordyceps spp.
effectiveness as an antidepressant regimen [24] and an
improvement of both hyperglycemia and depression in
rodents treated with Ophiocordyceps sinensis [25], there
is still inadequate number of scientific evidence in sup-
port of clinical use.
Our present study reported a close relationship in
phylogenetic and secondary metabolism profiles between
O. sinensis and O. formosana prompting the evaluation
of the effects of O. formosana on hyperglycermia and
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depression. Herein, we addressed potential medicinal
effects of O. formosana on hyperglycemia depression. By
employing an STZ-induced diabetes mouse model, we
identify the effects of OFE in comparison to Rosi via
measuring glucose tolerance, and assessing the
anxiety-like and depression-like behaviors of mice.
The expressions of adiponectin in plasma and adipose
tissue in situ were examined. In addition, the levels of
several neurotransmitters were measured to correlate
with the changes in psychological behaviors in re-
sponse to Ophiocordyceps formosana treatments in
STZ-induced diabetic mice.
Methods
Cultivation and extraction of Ophiocordyceps formosana
An epitypified Ophiocordyceps formosana (OF) was col-
lected, identified, cultivated and maintained by Wang
et al., as described in our previous study [26]. The vou-
cher specimen of Ophiocordyceps formosana has been
deposited in Leibniz-Institut DSMZ-Deutsche Samm-
lung von Mikroorganismen und Zellkulturen GmbH
designated as Ophiocordyceps formosana MUCHO 815-
DSM 32000. Ophiocordyceps formosana (OF) was main-
tained and cultivated according to our previous report
[26]. OF was grown on potato dextrose agar (PDA) con-
taining 0.4 % potato starch, 2 % dextrose, and 1.5 % agar
(Difco Becton Dickinson, Sparks, MD, USA) at 25 °C for
28 days. The colonies were then collected, lyophilized,
and pulverized by a homogenizer (SH100, KURABO
International Co., Tokyo, Japan) at 1300 rpm. The prep-
aration of Ophiocordyceps formosana extracts (OFE) was
proceeded by the standard operating procedure as previ-
ously described [26, 27]. In brief, 1 gram of OF powder
was mixed with deionized water at a ratio of 1:40 (w/v).
Thereafter, the extractions were carried out in a hot
water bath at 50 °C for 2 h along with sonication during
the first 30 min. The samples were then centrifuged at
3000 g for 20 min. The supernatant fractions were steril-
ized through 0.22 μm filters (Millipore, USA), and stored
at −80 °C. Each batch of OFE was subjected to content
analyses by high-performance liquid chromatography
(D2000 system, Hitachi Co., Tokyo, Japan).
HPLC analyses of Ophiocordyceps formosana extract (OFE)
The quality control of OFE was conducted by HPLC
(D2000 system, Hitachi Co., Tokyo, Japan) utilizing a
photodiarray detector (Primaide 1430, Hitachi Co.,
Tokyo, Japan). The analyses were performed using a RP-
18 column (150252 Purospher®STAR RP-18 endcapped
(5 μm) LiChroCART®250-4, Merck Co., New Jersey,
USA.) at a flow rate of 1 mL/min. The mobile phase was
20 % methanol in H2O and the absorbance was detected
at 260 nm. Two components in Cordecyps spp, adeno-
sine (A9252, Sigma-Aldrich Co., St. Louis, Missouri,
USA) and cordycepin (C3394, Sigma-Aldrich Co., St.
Louis, Missouri, USA), were used as standards for
quality controls.
STZ-induced diabetic mouse model
Thirty 8-week old male C57BL/6 mice (average weight =
20 ± 3 g) were purchased from the National Laboratory
Animal Center (Taipei, Taiwan). The environment was
maintained at 21 ± 3 °C, 50 ± 10 % relative humidity, and
under a 12 h:12 h light/dark cycle with free access to
food and water. All animal handling in this study are in
accordance with a protocol approved by the Institutional
Animal Care and Use Committee of National Taiwan
University (IACUC approval NO. NTU-102-EL-37). All
efforts were made to minimize animal suffering and to
reduce the number of animals used, including that the
animal sample size used for this current study was ana-
lyzed by G-power test with G*Power version 3.0.10.
The mice were first acclimatized for 7 days in the
standard housing condition. After acclimatization, dia-
betes was induced by administrating streptozotocin
(STZ) as previously described by Islam et al. [28, 29].
The STZ-induction mice were fasted for 6 h and before
administered with 40 mg/kg STZ (S0130, Sigma-Aldrich
Co., St. Louis, Missouri, USA) solution via intraperito-
neal (IP). STZ was given once a day for 5 days with 2
subsequent days for recovery. A total of 30 mice were
used in the present study with 24 mice as the STZ-
induction group, while the remainder 6 served as the
control group. A glucose tolerance test (GTT) was per-
formed to confirm diabetes pathophysiology after STZ
induction. STZ-induced mice were randomly divided
into 3 groups (n = 8 mice/group) subjected to oral gav-
age with 100 μL solution of 25 mg/mL OFE, 2 mg/mL
Rosi dissolved in PBS (R2408, Sigma-Aldrich Co., St.
Louis, Missouri, USA) or PBS alone once per day for
28 days. An additional 6 mice without STZ induction
were treated with PBS as the control group. Body weight
and food intake were recorded daily during the experi-
mental period. Mice are then sacrificed and islet cells
were isolated and quantified as previously reported [30].
The subcutaneous white adipose tissue (SAT) was
weighed and relative ratio of tissue-to-body weight was
calculated. Moreover, blood samples were collected prior
to sacrifice and stored at −80 °C for serological analyses,
including mouse insulin ELISA kit (EMINS, Thermo
Fisher Scientific, Waltham, Massachusetts, USA) and
adiponectin ELISA kit (DY1119, R&D systems Ind.,
Minneapolis, Missouri, USA).
Intraperitoneal glucose tolerance test (IPGTT)
Glucose intolerance was measured by IPGTT as modi-
fied from Andrikopoulos et al. [31]. In brief, mice were
fasted for 6 h prior to the 2 g/kg glucose administration
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by IP injection. IPGTT was performed before and after
the above treatments (Fig. 1d, Day 17 and Day 54,
respectively). Blood samples were collected from the
tail at 0, 30, 60, and 120 min after glucose infusion
to determine plasma glucose concentration utilizing a
glucometer (Accu-Chek® active, Roche Diagnostics
Ltd., Mannheim, Germany).
Animal behavioral tests
A series of anxiety-like and depression-related behavior
tests including open field test (OFT), elevated plus maze
(EPM), and tail suspension tests (TST) are conducted to
further characterize the depressive behavior associated
with hyperglycemia as reported by previous literature
[32–35].
An activity monitor enclosed in a sound-attenuated
chamber equipped with ventilation was used to video-
tape all test sessions. Each mouse was individually
placed in the center of an open-field apparatus (43.3 ×
21.7 × 20.8 cm3, made of clear plexiglass) and allowed to
explore freely for 60 min. Total travelled distance, dur-
ation, and velocity in the central and peripheral areas
were analyzed by TopScan v2.0 software (Clever Sys
Inc., Reston, VA, USA). The elevated plus maze is con-
sisted of 2 open arms (30-L × 5-W cm2 in size) and 2
close arms enclosed by 50 cm high white acrylic walls.
Open arms and close arms cross each other at right
angle and is located 50 cm above the floor. All arms
were made of white acrylic plates radiating from a cen-
tral platform (5 × 5 cm2) to form a “+” sign. Each mouse
was placed in the central platform area facing one of the
Fig. 1 Experimental timeline and procedure. a Ophiocordyceps formosana (OF) was collected from fields in Taiwan. b Cultivation of OF mycelia on
PDA plates with yellowish colonies. c Extracts of OF (OFE) were analyzed by a DAD-HPLC system. A representative HPLC profile of OFE allows
quantitative analyses of the indicated components, including adenosine and cordycepin. d Scheme for experimental timeline and procedures.
Eight week-old mice were first acclimated for 7 days prior to intraperitoneal (IP) injection with 40 mg/kg STZ solution for each mouse once a day
for constitutive 5 days and recovery for 2 days. Six mice were injected with PBS as a sham-control group. To monitor anxiety and insulin resistance
status for the STZ-treated and control group mice, at day 15, mice were conducted an anxiety behavior test by the open field test (OFT),
and intraperitoneal glucose tolerance test (IPGTT) was performed before and after the above treatments (Day 17 and Day 54, respectively).
The STZ-treated mice were then randomly divided into 3 different groups for oral gavage daily by 100 μL solution given of PBS, the
25 mg/mL OFE and 2 mg/mL Rosi, respectively. At day 48, several behavior tests, including OFT, EPM and TST, were used. All mice were
then fasting for 6 h before evaluating insulin sensitivity by GTT. The mice were sacrifice after 1-day recovery from GTT
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closed arms. The motion trail and time spent in the ap-
paratus were recorded for 5 min, and analyzed by TopS-
can v2.0 (Clever Sys Inc., Reston, VA, USA). Tail
suspension test is used to assess the depressive behavior
in animals. In brief, each mouse was taped by the tail
(2–3 cm from the tip of the tail) and suspended for
6 min at 35 cm above the floor [36, 37]. The mouse was
acoustically and visually isolated. The recorded data of
all test sessions were used to calculate the immobility
time, and subsequently the behavioral performance of
each mouse was scored by three investigators. Immobil-
ity was defined as when all paws and the head of the
mouse completely stop moving.
Immunohistolochemical analyses
Subcutaneous white adipose tissues (SAT) were isolated
and immediately fixed with 4 % paraformaldehyde, then
embedded into paraffin. Immunohistochemical analyses
were performed for examining adiponectin expressions
as described by Schindler et al. [38]. Tissue sections
were first deparaffinized, and subjected to antigen re-
trieval at 95 °C for 15 min in antigen retrieval buffer
(ab93680; Abcam, Cambridge, Massachusetts). Endogen-
ous peroxidase activity was blocked with 0.3 % H2O2 in
80 % methanol for 30 min. The sections were then
blocked with 1 % BSA and incubated with an anti-mouse
adiponectin antibody (ab22554; Abcam, Cambridge,
Massachusetts) for 18 h at 4 °C. Subsequently, the
sections were incubated with a goat anti-mouse sec-
ondary antibody (K500711, DakoCytomation Ltd., CA,
USA) for 30 min and visualized using a DakoCytomation
EnVision® + Duallink system HRP (DAB+) kit (K4065,
DakoCytomation Ltd., CA, USA). Slides were counter-
stained with hematoxylin, rinsed in ddH2O for 10 min,
and mounted with glycerin gelatin (GG1, Sigma-Aldrich
Co., St. Louis, Missouri, USA). Representative 40X images
were photographed and presented. Five areas of a section
were used for the signal intensity quantification. The
signal intensity of adiponectin expression in SAT was
calculated using Image J, an image-analysis program
(NIH, Bethesda, MD, USA) [39].
Measurement of monoamine levels in mouse brains
The monoamine levels in various limbic regions were
analyzed as described previously [40]. Briefly, brain was
extracted and prefrontal cortex, striatum and hippocam-
pus were isolated on an ice-chilled plate and weighed.
The brain tissues were homogenized in 1 mL of extract
solution consisting of 0.1 M HCl, 10−7 M ascorbic acid
and 50 pg/μL isoproterenol. Homogenates were then
centrifuged three times at 13200 rpm for 20 min at 4 °C
and filtered through a 0.22 μm filter (Millipore, Bedford,
USA). Supernatent was injected into a reverse C18 col-
umn (Hypersil GOLD aQ, 5 μm, 150 mm x 4.60 mm,
Thermo Fisher Scientific, Inc., Massachusetts, USA). The
concentrations of norepinephrine (NE, A7257, Sigma),
dopamine (DA, H60255, Sigma), 3,4-dihydroxyphenylace-
tic acid (DOPAC, 850217, Sigma), 5-hydroxytryptamine
(5-HT, H9523, Sigma), and 5-hydroxyindoleacetic acid (5-
HIAA, H8876, Sigma) were measured by HPLC coupled
with an electrochemical detector (P/N 70–9143 10 nA
range, 1 Hz filter, and 0.7 V AppE cell ECD, Shiseido Co.,
Tokyo, Japan) equipped with an auto-sampler (WPS-3000,
Shiseido Co., Tokyo, Japan). The mobile phase was 0.17 M
NaH2PO4, 0.63 mM ethylenediaminetetraacetic acid
(EDTA), 0.60 mM octane-1-sulfonic acid sodium salt, and
2 mM KCl in 20 % methanol, and adjusted to pH 3.30
with 85 % H3PO4. The flow rate was maintained in
0.6 mL/min. All the standards were purchased from Sigma
(St. Louis, MO, USA) and dissolved in the extraction solu-
tion for HPLC. The standard curves ranged from 0.01 to
5.0 ppm, and the detection limit of this system was 0.1 pg
for all samples.
Statistical analyses
Statistical significance was tested by one-way ANOVA
and Tukey’s multiple comparison test (SAS institute,
Cary, NC, USA). Data were expressed as mean ± S.E.M.
p values ≤ 0.05 were considered statistically significant.
The body weights were compared by the Student’s t test.
Data were expressed as mean ± S.E.M. # represents
p ≤ 0.05, and *** represents p ≤ 0.001.
Results
Extraction and chemical analyses of Ophiocordyceps
formosana
Ophiocordyceps formosana (Cordyceps s.l.) was estab-
lished, cultivated (Fig. 1a and b) then water extracted for
bioactive compound analyses by HPLC (Fig. 1a-c). Like
other known medicinal Cordyceps spp., the extract of O.
formosana contained adenosine and cordycepin (Fig. 1c),
potent bioactive components for medicinal use. Hence, we
sought for its potential benefit on diabetic complications.
OFE ameliorates the characteristics of STZ-induced
diabetic mice
To examine the medicinal benefit of the water extract of
O. formosana on diabetes, an STZ-induced diabetic ani-
mal model was employed. Consistent with features of
type I diabetes, STZ-induced diabetic mice displayed
body weight loss (Fig. 2a) and a fasting plasma glucose
value over 200 mg/dL (control = 119.5 ± 24.2 mg/dl and
STZ-PBS = 392.2 ± 38.7 mg/dl, p ≤ 0.001) (Fig. 2d). In
addition, the pancreatic β cell number was diminished in
STZ-induced diabetic mice, but neither Rosi nor OFE
treatment could rescue the number of β cells (data not
shown). However, the body weight was regained and the
subcutaneous adipose tissues (SAT) accumulated in the
Huang et al. BMC Complementary and Alternative Medicine  (2016) 16:310 Page 5 of 11
OFE-treated group compared to the PBS treated group.
The OFE treated mice exhibited a better outcome than
the Rosi-treated mice (Fig. 2b and c). Furthermore, the
plasma glucose and area under curve (AUC) of the
plasma glucose tolerance test (GTT) in the OFE treated
STZ-induced diabetic mice was reduced, indicating that
OFE could partially alleviate hyperglycemia induced by
STZ (Fig. 2d). However, the concentration of plasma insu-
lin did not show signs of recovery in OFE groups (Fig. 2e).
These results suggest that OFE is potentially capable of
ameliorating pathophysiological complications of STZ-
induced diabetic mice, but not mediate insulin recovery.
OFE increased adiponectin expression in plasma and
adipose tissue
Adiponectin is an adipokine highly correlated with fat
biogenesis and insulin sensitivity [4]. The level of
adiponectin in plasma was decreased by STZ compared
with the normal control group (Fig. 3a). As expected,
the level of plasma adiponectin was significantly elevated
by OFE treatment compared to PBS treatment. However,
OFE or Rosi treatment failed to rescue plasma adiponec-
tin level in comparison to the non-diabetic control
group (Fig. 3A). The enlarged adipocyte size in STZ-
diabetic mice was reduced in Rosi-treated mice and to a
greater extent in OFE-treated mice (Fig. 3b). Moreover,
STZ treatment lowered adiponectin level in subcutane-
ous adipose tissue, while Rosi treatment elevated adipo-
nectin level and OFE treatment showed a greater
increase compared to the non-diabetic controls (Fig. 3c).
Taken together, our data imply that OFE may up-
regulate the expression of adiponectin in SAT and
plasma leading to the promotion of biogenesis of SAT
in the diabetic mice.
Fig. 2 Ophiocordyceps formosana ameliorated the hyperglycermic characteristic of STZ-induced diabetic mice. a Changes in body weight of mice.
b Morphological appearance of visceral adiposity in mice. The arrows show the visualized adipose tissues. c The subcutaneous fat (SAT) to body
weight ratio. d The glucose concentration in plasmas at the end of the experiment. e The insulin concentration in plasma at the end of the experiment.
f The area under curve (AUC) of glucose tolerance test (GTT) after treatments. Data were expressed as mean ± S.E.M. # represents p≤ 0.05, STZ-PBS vs.
STZ-OFE and *** represents p≤ 0.001, control vs. STZ-PBS, STZ-Rosi and STZ- OFE. Results of two groups were compared by the Student’s t test. One way
ANOVA followed by Tukey’s post hoc test was performed for multiple comparisons. Mean in a row with different superscripts is significantly different
(p≤ 0.05). Values are mean ± SEM, n= 6 in control group and n= 8 in the all STZ-induced groups
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OFE reduces the anxiety and depression-like behaviors in
STZ-induced diabetic mice
To evaluate whether OFE confers benefits to the afore-
mentioned psychological complications, we conducted
animal behavioral tests, including open filed test (OFT),
elevated plus maze (EPM) and tail suspension test (TST)
[35]. The STZ-induced diabetic mice displayed anxiety-
and depression-related behaviors compared to control
group (Fig. 4), and the total travel distance decreased by
STZ induction (Fig. 4a). Conversely, the STZ-induced
diabetic mice treated with either Rosi or OFE showed an
increased duration time spent in the central zone of the
OFT (Fig. 4b). Moreover, the retention time spent in the
open arms of the EPM was extended in the STZ-OFE
group, indicating that OFE promoted exploratory behav-
iors (Fig. 4b and c). Similarly, results from the tail sus-
pension test showed an extended motionless duration
time in the STZ-PBS group (Fig. 4d), suggesting that the
STZ-induced diabetic mice expressed depression-like
behaviors. In contrast, the immobility time of the OFE
group was similar to that of the non-diabetic mice
(Fig. 4d). Collectively, our data demonstrated that OFE
is potent to ameliorate anxiety and depression-related
psychological complications associated with type I
diabetes.
Evaluation of various neurotransmitters levels in different
brain regions of STZ-induced diabetic mice treated by OFE
To elucidate the underlying mechanisms of OFE on alle-
viating the aforementioned psychological complications,
levels of neurotransmitters (i.e., DA and 5HT) and their
metabolites (i.e., DOPAC and 5HIAA) in the brain, in-
cluding the hippocampus, the striatum and the pre-
frontal cortex, were measured by ECD-HPLC (Table 1).
STZ-induced diabetic mice demonstrated reduced levels
of DA, DOPAC, 5HT and 5HIAA in the three brain re-
gions compared to control mice (Table 1). Intriguingly,
neurotransmitter levels were recovered by either Rosi or
OFE treatment, especially in the frontal cortex and stri-
atum (Table 1), which may contribute to the changes in
behaviors observed after Rosi and OFE treatment (Fig. 4).
Noticeably, the amount of norepinephrine (NE) in the
frontal cortex and hippocampus were increased by STZ-
treatment, but not in the striatum. Our data suggest that
OFE can alter the expression levels of neurotransmitters
in dopaminergic and serotonergic pathways.
Discussion
Type 1 diabetic (T1D) patients suffer weight loss, in-
crease fluid consumption and urination, as well as sev-
eral mental complications, such as irritability, anxiety,
and depression [41]. Unfortunately, current therapeutics
like, β-cell transplantation, immunosuppressive regimens
for pancreas transplantation or daily insulin injection
[1], are served to alleviate most of the complications in-
duced by T1D, but such treatments are limited and inef-
ficient,. Hence, our current study employed a diabetic
animal model induced by STZ to mimic the symptoms
of hyperglycemia and depression as observed in T1D
patients [42]. We found that the OFE treatment elevated
adiponectin levels, various brain neurotransmitter expres-
sions, and ameliorated various diabetes-related complica-
tions, including hyperglycermia and anxiety/depression
(Fig. 5). Our results indicate the pharmacological potential
Fig. 3 Ophiocordyceps formosana upregulated adiponectin expressions
in plasma and adipose tissues. a The levels of plasma adiponectin in
different STZ-induced treated groups. b Immunohistochemical staining
for adiponectin in adipose tissues. c The adiponectin-positive area of
each treated group was quantified by Image J. Scale bar = 50 mm,
under a 400x microscope. One-way ANOVA followed by Tukey’s post
hoc test was performed for multiple comparisons. Mean in a row with
different superscripts is significantly different (p≤ 0.05). Values are
mean ± SEM, n = 6 in control group and n = 8 in all STZ-treated groups
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for a newly established medicinal fungus, Ophiocordyceps
formosana, as an alternative and complementary
medicine.
Presently, several oral therapeutic regimens for treating
diabetes-related hyperglycemia and depression have been
widely developed and used. For instance, thiazolidinedione
(TZDs) drugs, such as rosiglitazone (Rosi), have been
reported to effectively control hyperglycemia in T2D [43].
In addition, Rosi has been shown to ameliorate depressive
behaviors by reduction of plasma corticosterone levels
[44]. However, several undesirable side effects, such as
stomach pain, diarrhea, heart failure and edema, are often
observed [45, 46]. Likewise, T1D patients show symptoms
of depression can be treated with oral antidepressants
Fig. 4 Ophiocordyceps formosana improved depressive-like behaviors in STZ-induced diabetic mice. a Locomotor activity in the open filed test
(OFT) (b) The ratio of retention time in the central zone to total duration time in the OFT. c The ratio of the retention time in the open arm to
total duration of the equipment (%) in the elevated plus maze (EPM). d The immobility time in the tail suspension test (TST). * represent p≤ 0.05,
Control-PBS vs. STZ-PBS. One way ANOVA followed by Tukey’s post hoc test was performed for multiple comparisons. Mean in a row with different
superscripts is significantly different (p≤ 0.05). Values are mean ± SEM, n = 6 in control group and n = 8 in all STZ-treated groups
Table 1 Expressions of various neurotransmitters, including the frontal cortex, striatum and hippocampus of brain, in mice
Brain Cortex Treatment Neurotransmitter (ng/g brain tissue)
DA DOPAC 5HT 5HIAA Norepinephrine
Frontal Cortex Control 1277.7 ± 332.8b 741.7 ± 115.5b 797.3 ± 72.8a 863.0 ± 47.2a 409.1 ± 107.3c
STZ-PBS 238.4 ± 27.00.2b 175.9 ± 55.5c 323.3 ± 93.4c 99.7 ± 11.5c 685.6.9 ± 34.4b
STZ-Rosi 851.5 ± 307.3b 615.3 ± 54.2b 594.5 ± 220.3bc 283.7 ± 39.9b 939.2 ± 81.8a
STZ-OFE 2343.2 ± 824.4a 1467.4 ± 136.6a 931.1 ± 45.6a 939.5.7 ± 59.8a 861.33 ± 84.4a
Striatum Control 986.8 ± 73.2b 1013.1 ± 101.6ab 936.7 ± 93.8a 863.0.0 ± 47.2b 916.52 ± 49.9a
STZ-PBS 806.1 ± 138.3 b 681.6 ± 61.2c 583.1 ± 97.4b 481.0 ± 33.9c 613.7 ± 26.2b
STZ-Rosi 1185.3 ± 423.9b 797.6 ± 103.1bc 613.8 ± 129.7b 491.7 ± 20.2c 731.8 ± 55.9b
STZ-OFE 2760.7 ± 323.0a 1069.9 ± 120.8a 693.2 ± 96.7ab 716.7 ± 57.1a 679.6 ± 65.7b
Hippocampus Control 288.5 ± 72.8a 111.7 ± 30.5b 1041.9 ± 103.6b 1040.7 ± 71.6a 257.6 ± 63.9c
STZ-PBS 84.6 ± 5.1bc 129.0 ± 46.9b 620.2 ± 66.2c 219.0 ± 5.9b 423.5 ± 85.8bc
STZ-Rosi 19.9 ± 6.2c 49.1 ± 28.0bc 864.3 ± 41.0b 185.4 ± 63.2b 702.9 ± 12.1a
STZ-OFE 255.1 ± 56.3a 317.4 ± 121.3a 1622.7 ± 83.0a 280.8 ± 61.5b 592.2 ± 107.9ab
DA: dopamine; DOPAC: 3,4-dihydroxy phenlactic acid; 5-HT: 5-hydroxytryptamine; 5-H1AA: 5-hydroxy indole acetic acid. One way ANOVA followed by Tukey’s post hoc
test was performed for multiple comparisons. Means in a row with different superscripts, such as a, b, c, ab, bc, is significantly different (p <= 0.05). Values are present as
mean ± SEM, n = 6 in control group and n = 8 in the ogher groups
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[47, 48]. For instance, selective serotonin reuptake in-
hibitors (SSRIs) are the most widely prescribed anti-
depressants in spite of numerous adverse side effects
[12]. Thus, there remains a need for regimens that
can ameliorate the symptoms of T1D with fewer side
effects. A natural product derived from an Ophiocor-
dyceps sinensis relative, O. formosana has relatively
lower toxicity in vitro [26] and as shown in this
current study seems to be effective in the STZ mouse
model for T1D. However, more studies remain needed
to evaluate its safety and indications.
Like Ophiocordyceps sinensis [49], O. formosana exhib-
ited a beneficial improvement in body weight of STZ-
induced mice and an increase in SAT (Fig. 2). The
extended plasma GTT in STZ-induced diabetic mice
was partially corrected by either Rosi or O. formosana
treatment (Fig. 2d). These results suggest that O. formo-
sana not only promotes glucose metabolism, but also in-
creases energy utilization in mice. Rosi is a PPAR-γ
agonist capable of increasing adiponectin expression,
synthesis and release [50]. Although adiponectin is ex-
clusively secreted from adipocytes, it is a circulating hor-
mone whose level in plasma is positively correlated with
insulin sensitivity and inversely associated with obesity
and T2D [21, 51]. Despite being highly expressed in
most fat tissues, the level of adiponectin is lower in vis-
ceral adipose tissues than in subcutaneous abdominal
adipose tissues (SAT), suggesting that SAT may be the
major contributor to circulating adiponectins [52]. Con-
sistently, our results showed that mice treated with 25 g/
ml/day of OFE for 28 days had increased SAT as well as
adiponectin in plasma and SAT (Fig. 3). We hypothesized
that O. formosana ameliorates insulin resistance via
up-regulation of adiponectin.
In addition to improvements in glucose sensitivity and
adipogenesis, an increase in plasma adiponectins is re-
portedly associated with reduced depressive disorders in
patients with diabetes [53, 54]. The intracerebroventricu-
lar infusion of recombinant globular adiponectin or re-
combinant full-length adiponectin reduced depressive-
like behavioral effects in normal weighted mice [21].
Furthermore, adiponectins alleviate depression-like be-
haviors attributed to their neuroprotective activity and
hippocampal neurogenesis modulation in mice [55]. Our
observations demonstrated that the increase in adipo-
nectin in plasma and adipose tissues by O.formosana
may have attributed to the improvement in behavioral
patterns in our mice treated with OFE.
O. formosana modulated monoamine neurotransmit-
ters, including dopamine, 5-HT and norepinephrine
(NE) in various brain regions, including the hippocam-
pus, amygdala and striatum. These brain regions take
part in regulating motion and rewarding as well as ex-
ecutive functions; therefore, their dysfunction has been
implicated in depression [56, 57]. Depressive illness is
linked with an insufficiency of brain monoamine neuro-
transmitters including dopamine, 5-HT and norepineph-
rine (NE) in these brain regions [12, 58]. Tail suspension
test utilized to assess antidepressant-like activity in mice
by observing their behavior under the inescapable stress
of being suspended above ground [59]. Administration
of OFE decreased immobility time and was accompanied
by increased amounts of DA and 5-HT in the hippocam-
pus and frontal cortex (Fig. 4d and Table 1). The striatum
is essential in mediating anxiety and reducing motivation
in patients with depression [60]. Two anxiety-related tests,
EPM and OFT, displayed increases in retention time in
the open arms and the central zone, respectively, in OFE-
treated STZ-induced mice along with increased DA and
5-HT in the striatum (Table 1). Although there are con-
flicting reports, we found that the level of NE was in-
creased in STZ-induced diabetic mice and is consistent
with previous reports [61, 62]. The locomotor activity
showed no significance between groups (data now shown),
suggesting that the improvement of anti-depressive-like
behaviors by OFE was not caused by hyperactivity. Taken
together, O. formosana ameliorates both anxiety-like and
depressive-like behaviors in STZ-induced diabetic mice.
The increased levels of various neurotransmitters in some
brain regions in these mice suggest that the changes in be-
haviors may result from modulation of neurotransmitters.
Rosiglitazone (Rosi) has been applied for the clinical
treatment of T1D patients with depression [63]. After
12 weeks of treatment with Rosi, severity of depression
based upon the Hamilton Depression Rating Scale and
the Clinical Global Impression Scale was improved [15].
Fig. 5 Putative mechanisms for OFE in improving insulin resistance
and depression. OFE promotes the expression of adiponectin, which
is an adipokine involved in insulin sensitivity and anti-depression. In
addition, the neurotransmitters (5-HT and dopamine) in brain regions
were also elevated by OFE, which also leads to anti-depression
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The results indicated that improvement of insulin
resistance is a prospective treatment for alleviation of
depression. Recently, an emerging relationship between
inflammation and depression has led to the use of anti-
inflammatory drugs to ameliorate the symptoms of de-
pression [64, 65]. Here, we provide a new approach to
ameliorate insulin insufficiency and depression medi-
ated by Ophiocordyceps formosana; the mechanism was
suggested to be via the upregulation of adiponectins.
Although some minor components of Cordyceps spp.,
such as cordycepin, polysaccharides and trace elements
like vanadium, are reported to be responsible for the
antidepressant-like activities [25], further investigation
is necessary to identify the constituents of Ophiocordy-
ceps formosana rendering the anti-hyperglycemic and
anti-depression activities.
Conclusion
To our knowledge, our current study demonstrated, for
the first time, the medicinal merit of Ophiocordyceps for-
mosana on T1D and hyperglycemia-induced depression.
Our results revealed OFE improved glucose utilization
by promoting adiponectin expression in STZ-induced
diabetic mice. The administration of OFE also modulated
the expression of monoamine neurotransmitters and their
metabolites (i.e., 5-HT and DOPA). Collectively, this study
provided a potential usage of O. formosana extracts to
counteract hyperglycemia and depression complications.
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